ENTITY
Hangzhou Tigermed Consulting (A)

Hangzhou Tigermed Consulting (A) (300347 CH)

95
Analysis
Health CareChina
Hangzhou Tigermed Consulting Company Limited provides professional clinical research services for domestic and foreign pharmaceutical and health-related research and development. The Company's main services include clinical trial technology services, data management, and statistical analysis.
more
Refresh
13 Nov 2015 17:14

Quick Note - Almost at the Finishing Line

Latest Update:Glass Lewis and ISS have advised Wuxi's shareholders to approve the offer from the consortium. We believe Shareholders will vote in...

Share
17 Jul 2015 01:01

WuXi PharmaTech: How to Argue for a Few Dollars More

WuXi PharmaTech's recent placements of stock of its NEEQ-listed Syn-The-All Pharmaceutical Co. subsidiary have been at a substantially higher...

Share
01 May 2015 06:34

WuXi's Chairman and Ally Bridge Offer $46/ADS in Going Private Bid

WuXi's Founder, Chairman and CEO, Dr. Ge Li and private equity firm Ally Bridge have made a non-binding offer to take the company private for...

Share
21 Apr 2015 07:53

Increasing Opportunities in Emerging Market CROs

Life sciences R&D spending growth in Asia is outpacing the developed world (US, Canada, and Europe). An article from the January 2, 2014,...

Share
x